SPDR S&P Biotech ETF (XBI)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 25, 2025 | $0.01 | 2025-06-23 | 2025-06-23 |
| March 26, 2025 | $0.01 | 2025-03-24 | 2025-03-24 |
| December 26, 2024 | $0.00 | 2024-12-23 | 2024-12-23 |
| September 25, 2024 | $0.02 | 2024-09-23 | 2024-09-23 |
| June 26, 2024 | $0.11 | 2024-06-24 | 2024-06-24 |
Dividends Summary
- SPDR S&P Biotech ETF has issued 44 dividend payments over the past 18 years
- The most recent dividend was paid 87 days ago, on June 25, 2025
- The highest dividend payed out to investors during this period was $0.671424 per share
- The average dividend paid during this period was $0.12 per share.
Company News
The biotech sector is showing signs of stabilization with increasing venture capital funding and family office investments. Experts suggest careful selection of biotech companies with strong science, sufficient capital, and near-market products.
Bank of America's chief investment strategist Michael Hartnett recommends buying long-duration bonds as yields stabilize and the potential for lower government deficits under the Trump administration. He suggests four ETFs to watch: iShares 20+ Year Treasury Bond ETF (TLT), SPDR S&P Biotech ETF (XBI), SPDR Homebuilders ETF (XHB), and SPDR Utilities Select Sector Fund (XLU).
The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup. The appointment of RFK Jr. to lead the Department of Health and Human Services has spooked investors with his controversial policies and vaccine skepticism, leading to a decline in sector giants like Pfizer.
The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeutics.